
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx Inc. demonstrates a robust financial outlook, with a reported $483 million in combined revenue, reflecting an 18% year-over-year increase, and management projecting peak sales exceeding $1 billion by 2029. The company is actively enhancing the prescribing depth and breadth of its products, with notable growth seen in the XPHOZAH segment, particularly a 41% increase in non-Medicare prescriptions in 2025, driven by strategic investments in patient assistance and sales initiatives. Furthermore, Ardelyx's ongoing Phase 3 trial (ACCEL) for IBSRELA aims to expand its market reach by enrolling patients with chronic idiopathic constipation, with results anticipated in the latter half of 2026 and 2027, suggesting continued potential for revenue growth.
Bears say
Ardelyx Inc. faces significant challenges that contribute to a negative outlook on its stock, particularly pertaining to its IBSRELA product's expected performance, with anticipated revenue reflecting an 18% quarter-over-quarter decline in 1Q26 despite a total forecast of $422 million for FY26. This projection is coupled with a costly monthly price point of approximately $2,300 and decreasing gross-to-net revenue adjustments, which signal potential weaknesses in market penetration and pricing resilience. Additionally, the company's reported net loss of $0.4 million in 4Q25 and low adherence rates among patients utilizing phosphate binders highlight underlying operational and commercial risks that could hinder its financial stability and growth prospects.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares